Evidence map›Paper›PMID 31689976›Full record

ArticleMolecules (Basel, Switzerland)2019

Isorhamnetin Has Potential for the Treatment of

Anil Kumar Chauhan, Jieun Kim, Yeongjoon Lee, Pavithra K Balasubramanian, Yangmee Kim

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
4.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Isorhamnetin fromFrontiers in nutrition · 2026
    Article
  6. Review
  7. Review
  8. Protective Effects of Rhamnetin in Carbapenem-ResistantInternational journal of molecular sciences · 2023
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Fruits ofFrontiers in pharmacology · 2022
    Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Anil Kumar ChauhanDepartment of Bioscience and Biotechnology, Research Institute for Bioactive-Metabolome Network, Konkuk University, Seoul 05029, Korea. chauhananil48@konkuk.ac.kr.
Jieun KimDepartment of Bioscience and Biotechnology, Research Institute for Bioactive-Metabolome Network, Konkuk University, Seoul 05029, Korea. za3524@konkuk.ac.kr.
Yeongjoon LeeDepartment of Bioscience and Biotechnology, Research Institute for Bioactive-Metabolome Network, Konkuk University, Seoul 05029, Korea. lyj7956@konkuk.ac.kr.
Pavithra K BalasubramanianDepartment of Bioscience and Biotechnology, Research Institute for Bioactive-Metabolome Network, Konkuk University, Seoul 05029, Korea. Pavithra@konkuk.ac.kr.
Yangmee KimDepartment of Bioscience and Biotechnology, Research Institute for Bioactive-Metabolome Network, Konkuk University, Seoul 05029, Korea. ymkim@konkuk.ac.kr.ORCID 0000-0001-6438-4718
Konkuk University · KR

Funding

National Research Foundation of Korea 2019R1H1A2079889
6 · The paper itself

Abstract

Isorhamnetin is a flavonoid that is abundant in the fruit of

Indexed as

AnimalsEscherichia coliFemaleInflammationMiceMice, Inbred BALB CQuercetinSepsisSurface Plasmon ResonanceToll-Like Receptor 43-methylquercetinQuercetinToll-Like Receptor 4bacterial sepsisflavonoidinflammationisorhamnetintoll-like receptor 4

Identifiers

PMID31689976
PMCPMC6864442
OpenAlexW2988001206

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.